NASDAQ:VERA Vera Therapeutics (VERA) Stock Price, News & Analysis $37.88 +1.69 (+4.67%) As of 10:38 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Vera Therapeutics Stock (NASDAQ:VERA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vera Therapeutics alerts:Sign Up Key Stats Today's Range$36.55▼$38.0050-Day Range$34.52▼$45.0452-Week Range$18.76▼$56.05Volume94,967 shsAverage Volume1.14 million shsMarket Capitalization$2.70 billionP/E RatioN/ADividend YieldN/APrice Target$79.60Consensus RatingModerate Buy Company Overview Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity. Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs. The company concentrates on high-unmet-need autoimmune disorders, pursuing therapies that can broadly benefit patient populations worldwide. Through strategic partnerships and disciplined clinical execution, Vera Therapeutics seeks to accelerate the translation of its immunomodulatory candidates. The leadership team at Vera Therapeutics brings extensive experience in biologics development, translational research and regulatory affairs, supported by an accomplished scientific advisory board. As a NASDAQ‐listed company trading under the ticker VERA, it is well positioned to drive its innovative platform toward key clinical milestones and deliver new treatment options for immune-mediated diseases.AI Generated. May Contain Errors. Read More Vera Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreVERA MarketRank™: Vera Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 424th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingVera Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 10 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialVera Therapeutics has a consensus price target of $79.60, representing about 110.1% upside from its current price of $37.88.Amount of Analyst CoverageVera Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Vera Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vera Therapeutics are expected to grow in the coming year, from ($5.54) to ($3.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vera Therapeutics is -6.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vera Therapeutics is -6.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVera Therapeutics has a P/B Ratio of 4.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.53% of the float of Vera Therapeutics has been sold short.Short Interest Ratio / Days to CoverVera Therapeutics has a short interest ratio ("days to cover") of 6.93.Change versus previous monthShort interest in Vera Therapeutics has recently increased by 1.11%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVera Therapeutics does not currently pay a dividend.Dividend GrowthVera Therapeutics does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment0.07 News SentimentVera Therapeutics has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Vera Therapeutics this week, compared to 4 articles on an average week.Search Interest5 people have searched for VERA on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows2 people have added Vera Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership2.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Vera Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,416,902.00 in company stock.Percentage Held by Insiders15.90% of the stock of Vera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.21% of the stock of Vera Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vera Therapeutics' insider trading history. Receive VERA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VERA Stock News HeadlinesVera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 11 at 2:30 AM | americanbankingnews.comThe Bull Case For Vera Therapeutics (VERA) Could Change Following Atacicept’s FDA Priority Review And Ramp-UpMay 11 at 1:11 AM | finance.yahoo.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.May 11 at 1:00 AM | InvestorPlace (Ad)Vera Therapeutics (VERA) Gets a Buy from LifeSci CapitalMay 8 at 10:34 PM | theglobeandmail.comVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 8 at 4:05 PM | globenewswire.comVera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial ResultsMay 7, 2026 | globenewswire.comVera Therapeutics to Participate in the Bank of America Securities 2026 Health Care ConferenceMay 4, 2026 | globenewswire.comVera Therapeutics (NASDAQ:VERA) CEO Marshall Fordyce Sells 22,951 SharesApril 16, 2026 | insidertrades.comSee More Headlines VERA Stock Analysis - Frequently Asked Questions How have VERA shares performed this year? Vera Therapeutics' stock was trading at $50.64 at the beginning of 2026. Since then, VERA shares have decreased by 25.2% and is now trading at $37.88. How were Vera Therapeutics' earnings last quarter? Vera Therapeutics, Inc. (NASDAQ:VERA) announced its earnings results on Thursday, May, 7th. The company reported ($1.69) EPS for the quarter, missing analysts' consensus estimates of ($1.33) by $0.36. When did Vera Therapeutics IPO? Vera Therapeutics (VERA) raised $65 million in an initial public offering on Thursday, May 13th 2021. The company issued 4,350,000 shares at $14.00-$16.00 per share. Jefferies, Cowen and Evercore ISI served as the underwriters for the IPO. Who are Vera Therapeutics' major shareholders? Vera Therapeutics' top institutional investors include Pictet Asset Management Holding SA (1.47%), Candriam S.C.A. (0.67%), Dimensional Fund Advisors LP (0.39%) and Bank of New York Mellon Corp (0.25%). Insiders that own company stock include Commodore Capital Lp, Maha Katabi, Marshall Fordyce, Beth C Seidenberg, Sean Grant, Joseph R Young, Laurence Matthew Skelton, Robert Brenner, David Lee Johnson, William D Turner, Celia Lin and Patrick G Enright. View institutional ownership trends. How do I buy shares of Vera Therapeutics? Shares of VERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vera Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vera Therapeutics investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE) and Arista Networks (ANET). Company Calendar Last Earnings5/07/2026Today5/11/2026Bank of America Global Healthcare Conference 20265/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 2 weeks, VERA's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VERA CIK1831828 Webveratx.com Phone650-770-0077FaxN/AEmployees40Year Founded2016Price Target and Rating Average Price Target for Vera Therapeutics$79.60 High Price Target$110.00 Low Price Target$33.00 Potential Upside/Downside+110.1%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($5.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$299.61 million Net MarginsN/A Pretax MarginN/A Return on Equity-74.86% Return on Assets-60.18% Debt Debt-to-Equity Ratio0.15 Current Ratio13.64 Quick Ratio13.64 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.48 per share Price / Book4.47Miscellaneous Outstanding Shares71,360,000Free Float60,010,000Market Cap$2.70 billion OptionableOptionable Beta0.96 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:VERA) was last updated on 5/11/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first t...Paradigm Press | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredTrade this between 9:30 and 10:45 am ESTThe first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
